Acute interstitial pneumopathy associated with docetaxel hypersensitivity

Area of Science:

• Oncology
• Pulmonology
• Clinical Pharmacology

Background:

• Docetaxel is a chemotherapy agent used in cancer treatment.
• Previous studies and case reports have indicated acute pulmonary toxicity associated with docetaxel.
• Docetaxel-induced interstitial pneumonopathy is a severe condition potentially leading to respiratory failure.

Observation:

• A breast cancer patient developed respiratory failure after two cycles of docetaxel.
• The patient experienced similar symptoms and radiological findings after receiving paclitaxel.
• Clinical, pathological, and radiographic data suggested a hypersensitivity reaction to docetaxel as the cause.

Findings:

• The patient recovered after corticosteroid treatment without requiring mechanical ventilation.
• The case suggests taxanes, as a class, may induce similar pulmonary adverse reactions.
• Pulmonary toxicity from docetaxel can manifest as interstitial pneumonopathy.

Implications:

• This case underscores the potential for taxane-based chemotherapy to cause severe pulmonary toxicity.
• Physicians should consider hypersensitivity reactions when patients develop pulmonary symptoms during taxane treatment.
• Rechallenging patients with taxanes after a pulmonary toxic reaction is not recommended; alternative chemotherapy classes should be considered.